CMV si aetioasdcs wtih nceitifng onrag laatrpsnnt et.pisatn MVC is edtirstatnm avi uaelsx ctatc,no ragon lnpasttrna, or creilayvlt avi pe.tnclaa iocnvetaitRa fo MVC ccours in eht merdui.oppssnsuem
rOnag lnsataptrn tepsniat ear ta an nsriecaed irsk fo MVC nou.npmaie
he wsa ernev igenv irgolinaccv - i used ttha as a eulc orve nlprnttaas tjorecnie
Wyh udlwo htis not be ctaeu tastnapnrl neeiocrtj anlgdei ot SDAR? hTe ecatnneiir is etldevae, and I ees nay saorne hyw it oludw be eetedalv onyebd ejrtenico
via @sammyj98 via UpToDate:
Universal prophylaxis with valganciclovir or ganciclovir is typically given to patients at risk for cytomegalovirus (CMV) reactivation (eg, seropositive recipients and those with seropositive donors). The duration of therapy often depends on the type of organ transplanted, the risk status of the patient, and individual institutional practice. Some transplant centers prefer to use a pre-emptive approach (eg, routine CMV viral load monitoring within initiation of treatment when reactivation becomes evident) for specific patient populations.
submitted by ∗amorah(115)
It can be re-accessed by making a purchase.
Purchase your membership here
$279$49 65% OFFeerFv >- leur uot etfl rvelrinutac afueilr T -MXSMP hliyppoasrx ;&tg- erlu tou syimcPoetuns ycviKnjoeeiidr slaatptnnr but on /BCCBRW in niure g&-t; reul tou anpnlrtsta jerotinec
nvaiLeg MCV adn iatlcapy atecbiomcumyr as teh mngaieinr tow .posnoit CVM si mero elkyil ni a antlsrpant ae.pitnt
$279$49 65% OFF